Memantine Donepezil Fixed Ratio CNS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS-related conditions, such as Alzheimer's disease, face challenges in achieving therapeutic efficacy while minimizing side effects due to the complex interplay of neuronal pathways and the need for frequent dosing of NMDA receptor antagonists, which can lead to patient compliance issues and adverse effects.
Innovation Solution
A pharmaceutical composition combining an NMDA receptor antagonist, like memantine, with an acetylcholinesterase inhibitor, such as donepezil, in a controlled or extended release form to optimize therapeutic benefits and reduce side effects by stabilizing the concentration ratio and reducing the frequency of dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor antagonists are administered frequently to maintain therapeutic levels, then therapeutic efficacy is improved, but patient compliance deteriorates and adverse effects increase
Solution Approach 1:
The patent combines memantine (NMDA receptor antagonist) and donepezil (acetylcholinesterase inhibitor) into a single fixed-ratio combination product. This merging of two separate medications into one unified formulation allows patients to take fewer pills and simplifies their dosing routine, directly addressing the compliance issue while maintaining the therapeutic benefits of both drugs.
Solution Approach 2:
The patent establishes a specific fixed ratio between memantine and donepezil (5:1 by weight, corresponding to 10mg:2mg or 20mg:4mg) to optimize the pharmacological effect. This parameter optimization ensures that the combination achieves synergistic therapeutic efficacy while reducing the total dosing frequency required, thereby improving patient compliance.
2Adaptability or versatility
If multiple separate medications are used to treat CNS disorders, then therapeutic coverage is improved, but treatment complexity increases
Solution Approach 1:
The patent merges memantine and donepezil into a single combination product that provides dual therapeutic coverage for CNS disorders. This unified formulation maintains the adaptability and versatility of treating multiple conditions while significantly reducing treatment complexity compared to managing two separate medications with different dosing schedules.
3Reliability
If higher doses of NMDA receptor antagonists are administered to improve therapeutic effect, then therapeutic efficacy is improved, but adverse effects increase
Solution Approach 1:
The patent optimizes the dosage ratio between memantine and donepezil to a fixed 5:1 ratio, which has been determined to provide the optimal balance between therapeutic efficacy and adverse effect profile. This parameter optimization allows for effective treatment at lower individual doses compared to monotherapy, reducing the risk of adverse effects while maintaining therapeutic benefit.
Solution Approach 2:
The combination formulation acts as an intermediary that modulates the pharmacological interaction between memantine and donepezil. By establishing a controlled fixed ratio, the formulation ensures that the synergistic therapeutic effect is maximized while the adverse effects are minimized, effectively mediating between the two active ingredients to achieve safe and effective treatment.
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3C
AI summary
The invention relates to methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.